Stockreport

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia [Seeking Alpha]

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF XFOR's 4WARD Phase 3 trial in CN will be key. This could unlock a sizeable TAM across 15,000 patients with moderate-to-severe symptoms. Mavorixafor's initial Phase 2 [Read more]